Trial Profile

Post-Marketing Surveillance (Usage Results Study) of Brigatinib in the Treatment of Adult Patients for Approved Indications in South Korea

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brigatinib (Primary)
Indications Carcinoma; Non-small cell lung cancer
Focus Adverse reactions
Sponsors Takeda

Most Recent Events

16 Jul 2026 Status changed from recruiting to completed.
15 Jan 2025 Planned number of patients changed from 616 to 257.
29 Sep 2021 Planned number of patients changed from 600 to 616.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com